NR
Nurix Therapeutics, Inc.
NRIX · NASDAQ
$25.44 -1.03% (-$0.27)
1M -3.16%
Market Cap $2.64B
P/E Ratio -
Div. Yield -
ROE 76.09%
Piotroski F-Score Weak
2/9Valuation
9 /100
Expensive P/B 6.56x
P/S 71.81x
EV/EBITDA N/A
Growth
100 /100
Growing Book val. growth 21.05%
Rev. growth 29.55%
FCF growth N/A
Profitability
0 /100
Weak Net margin 928.44%
Op. margin 982.37%
FCF margin 828.28%
Quality
1 /100
Poor ROE 76.09%
ROA 63.74%
Asset turnover 0.07x
Debt
100 /100
Low Current ratio 6.34x
Debt/Equity 0.14x
Net debt/EBITDA N/A
Stability
29 /100
Unstable Rev. volatility 65.14%
EPS volatility 20.75%
Profitable years 0
Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe
Întreabă StockBot despre NRIX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Arthur T. Sands
Employees
317
Headquarters
Brisbane
Evenimente viitoare
08 OCT.
Earnings
Upcoming earnings report